The multinational company Bayer introduced a new drug to treat patients with type 2 diabetes in the Dominican Republic, hoping to stop the progression of kidney damage in people with the disease.
This is “Finerenone”, which works by blocking inflammation, reducing fibrosis and reducing the level of albumin (a protein whose presence in urine is evidence of kidney disease) in patients with chronic kidney disease and type 2 diabetes. does.
Dr. Mauricio Chávez, Cardiorenal Medical Advisor at Bayer, explained that finerenone is an indicated therapy for type 2 diabetic adults with chronic kidney disease. What it does Block the action of certain hormones (steroids) produced by the body that can damage the heart and kidneys, blocking the inflammatory and fibrosis processes in these organs.
The doctor said the drug may reduce the risk of worsening of kidney disease and the need for hospitalization for heart failure, as well as reduce the risk of cardiovascular events.
The most recent global figures estimate that 90% of all people with diabetes are classified as type 2; and of these two out of five; That is, about 40% will develop chronic kidney disease.
Chronic kidney disease is a very serious complication in patients with type 2 diabetes and its timely detection is important so that it can be treated and the patient can be given a quality life.
However, according to experts, there are no symptoms or signs in the early stages.
In this sense, Dr. Chávez explained that kidney damage is silent; Normally the patient will not feel anything. Many times the patient goes to their doctor when they notice some symptoms and this can happen when the patient starts to accumulate fluid; That is, his face, eyelids, hands are swollen, he has difficulty urinating or he urinates little, he has fatigue, nausea, vomiting, persistent itching of the skin. These are signs that occur when the disease is already very advanced.